Healthcare Sector Outlook: CVS and Vertex Prospects
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy CVS?
Source: Fool
- CVS Recovery: CVS Health's share price surged over 70% in 2025, and it is expected to maintain this growth momentum in 2026, despite plans to scale back its Medicare Advantage business to enhance long-term profitability, indicating a strategic shift towards sustainable growth.
- Strategic Focus: By exiting the Obamacare marketplace, CVS aims to concentrate on long-term profitability, which may not significantly impact short-term financial results but is likely to enhance its competitive position in the future.
- Vertex Drug Progress: Vertex Pharmaceuticals anticipates that its new drugs, Journavx and Casgevy, will generate at least $500 million in sales in 2026, which, while modest compared to its total revenue of $12 billion in 2025, highlights the potential for product line diversification.
- Clinical Advancements: Vertex plans to seek approval for its Type 1 diabetes drug, zimislecel, and will release phase 3 study data for treatments targeting IgA nephropathy and APOL-1 mediated kidney disease, further strengthening its market position and product portfolio.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 79.900
Low
91.00
Averages
96.71
High
105.00
Current: 79.900
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, diagnostic testing and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Invests €432 Million to Expand Wegovy Production
- Investment Expansion: Novo Nordisk announced a €432 million ($506 million) investment in Ireland to expand production capacity for the Wegovy pill, aiming to meet future global demand, particularly outside the U.S. market.
- Competitive Pressure: This investment follows Novo losing market share to Eli Lilly, with analysts noting that despite competitive pressures, this move demonstrates the company's commitment to the oral medication market, potentially helping to restore market confidence.
- Supply Assurance: Novo has stated that it has resolved supply issues for Wegovy and has enough product to meet U.S. demand; however, challenges remain in meeting global demand, especially as it seeks to launch in other countries.
- Future Outlook: The construction projects in Ireland are set to be completed gradually between 2027 and 2028, expected to include technological upgrades of existing facilities, further enhancing Novo's competitiveness in the obesity drug market, particularly in its strategic focus on oral medications.
See More
Healthcare Sector Outlook: CVS and Vertex Prospects
- CVS Recovery: CVS Health's share price surged over 70% in 2025, and it is expected to maintain this growth momentum in 2026, despite plans to scale back its Medicare Advantage business to enhance long-term profitability, indicating a strategic shift towards sustainable growth.
- Strategic Focus: By exiting the Obamacare marketplace, CVS aims to concentrate on long-term profitability, which may not significantly impact short-term financial results but is likely to enhance its competitive position in the future.
- Vertex Drug Progress: Vertex Pharmaceuticals anticipates that its new drugs, Journavx and Casgevy, will generate at least $500 million in sales in 2026, which, while modest compared to its total revenue of $12 billion in 2025, highlights the potential for product line diversification.
- Clinical Advancements: Vertex plans to seek approval for its Type 1 diabetes drug, zimislecel, and will release phase 3 study data for treatments targeting IgA nephropathy and APOL-1 mediated kidney disease, further strengthening its market position and product portfolio.
See More
CVS Health and Vertex Pharmaceuticals Outlook
- CVS Health Strategic Shift: CVS Health plans to scale back its Medicare Advantage business in 2026, which may not significantly impact financial results in the short term but aims to enhance long-term profitability, thereby strengthening its leadership position in the healthcare sector.
- Stock Price Recovery: In 2025, CVS Health's share price soared over 70% due to improved financial results, laying a solid foundation for continued growth in 2026, reflecting the company's deep roots in the U.S. healthcare ecosystem and strong customer relationships.
- Vertex Pharmaceuticals New Product Progress: Vertex Pharmaceuticals expects its new products, Journavx and Casgevy, to generate at least $500 million in sales in 2026, which, while modest, will provide crucial support for the company's future revenue growth.
- Clinical and Regulatory Advances: Vertex plans to seek approval for its investigational medicine zimislecel for Type 1 diabetes in 2026 and release phase 3 study data for next-gen programs, further enhancing the diversity and competitiveness of its product lineup.
See More
Trump Administration Halts $259 Million Medicaid Funds to Minnesota
- Medicaid Funding Suspension: U.S. Vice President JD Vance announced the withholding of $259 million in Medicaid funds from Minnesota due to the state's failure to prevent the theft of federal funds, highlighting significant regulatory shortcomings in social welfare programs.
- State Government Pushback: Minnesota Governor Tim Walz retaliated on social media, accusing the Trump administration of attempting to punish states led by Democrats, illustrating the political tensions intertwined with healthcare policy.
- Audit Findings Impact: Medicaid program overseer Dr. Mehmet Oz stated that the payment halt follows audit findings, requiring Minnesota to propose a comprehensive corrective action plan within 60 days, emphasizing the stringent scrutiny of Medicaid fund usage.
- Nationwide Enrollment Pause: Additionally, a six-month nationwide pause on Medicaid enrollment for durable medical equipment suppliers was announced, aimed at addressing fraud risks among these providers, thereby intensifying oversight of the Medicaid system.
See More
Novo Nordisk Faces Market Pressures and Competition
- Market Share Decline: Despite being the first to launch a GLP-1 weight loss drug, Novo Nordisk's market share has fallen to about 40%, while rival Eli Lilly holds 60%, indicating a significant competitive disadvantage that could hinder future growth potential.
- Sales Forecast Downgrade: Novo Nordisk anticipates a 5% to 13% decline in sales and profits for 2026, marking the first annual sales drop since 2017, reflecting the company's vulnerability amid fierce competition and pricing pressures, which may further erode investor confidence.
- Drug Development Challenges: The disappointing trial results of Novo's next-generation weight loss drug CagriSema against Eli Lilly's Zepbound led to a more than 16% drop in stock price on the day of the announcement, significantly diminishing analysts' confidence in its commercial potential and possibly affecting future market performance.
- Increasing Pricing Pressure: The decline in GLP-1 drug prices in the U.S. is weighing on Novo Nordisk's revenue and profitability, especially since the U.S. market has accounted for over half of its total sales since 2023, making future pricing strategies critical for the company's ability to regain growth.
See More
Energy and Healthcare Stocks Underperform
- Energy Sector Decline: As of midday Tuesday, energy companies are down 0.4%, with ONEOK Inc (OKE) and EQT Corp (EQT) showing losses of 5.2% and 1.7%, respectively, indicating sector weakness that may impact investor confidence.
- ETF Performance Analysis: The Energy Select Sector SPDR ETF (XLE) is down 0.2% on the day but up 23.09% year-to-date, suggesting that despite short-term volatility, the long-term trend remains positive, potentially attracting more investor interest.
- Healthcare Sector Weakness: The healthcare sector is up 0.3% overall, yet Molina Healthcare Inc (MOH) and CVS Health Corporation (CVS) are down 4.2% and 3.7%, respectively, reflecting challenges faced by the sector that may influence future investment decisions.
- ETF Tracking Status: The Health Care Select Sector SPDR ETF (XLV) is down 0.3% on the day and up 2.09% year-to-date, showing some resilience despite short-term underperformance, which may provide investors with opportunities for risk diversification.
See More
Novo Nordisk Invests €432 Million to Expand Wegovy Production
- Investment Expansion: Novo Nordisk announced a €432 million ($506 million) investment in Ireland to expand production capacity for the Wegovy pill, aiming to meet future global demand, particularly outside the U.S. market.
- Competitive Pressure: This investment follows Novo losing market share to Eli Lilly, with analysts noting that despite competitive pressures, this move demonstrates the company's commitment to the oral medication market, potentially helping to restore market confidence.
- Supply Assurance: Novo has stated that it has resolved supply issues for Wegovy and has enough product to meet U.S. demand; however, challenges remain in meeting global demand, especially as it seeks to launch in other countries.
- Future Outlook: The construction projects in Ireland are set to be completed gradually between 2027 and 2028, expected to include technological upgrades of existing facilities, further enhancing Novo's competitiveness in the obesity drug market, particularly in its strategic focus on oral medications.
See More
Healthcare Sector Outlook: CVS and Vertex Prospects
- CVS Recovery: CVS Health's share price surged over 70% in 2025, and it is expected to maintain this growth momentum in 2026, despite plans to scale back its Medicare Advantage business to enhance long-term profitability, indicating a strategic shift towards sustainable growth.
- Strategic Focus: By exiting the Obamacare marketplace, CVS aims to concentrate on long-term profitability, which may not significantly impact short-term financial results but is likely to enhance its competitive position in the future.
- Vertex Drug Progress: Vertex Pharmaceuticals anticipates that its new drugs, Journavx and Casgevy, will generate at least $500 million in sales in 2026, which, while modest compared to its total revenue of $12 billion in 2025, highlights the potential for product line diversification.
- Clinical Advancements: Vertex plans to seek approval for its Type 1 diabetes drug, zimislecel, and will release phase 3 study data for treatments targeting IgA nephropathy and APOL-1 mediated kidney disease, further strengthening its market position and product portfolio.
See More
CVS Health and Vertex Pharmaceuticals Outlook
- CVS Health Strategic Shift: CVS Health plans to scale back its Medicare Advantage business in 2026, which may not significantly impact financial results in the short term but aims to enhance long-term profitability, thereby strengthening its leadership position in the healthcare sector.
- Stock Price Recovery: In 2025, CVS Health's share price soared over 70% due to improved financial results, laying a solid foundation for continued growth in 2026, reflecting the company's deep roots in the U.S. healthcare ecosystem and strong customer relationships.
- Vertex Pharmaceuticals New Product Progress: Vertex Pharmaceuticals expects its new products, Journavx and Casgevy, to generate at least $500 million in sales in 2026, which, while modest, will provide crucial support for the company's future revenue growth.
- Clinical and Regulatory Advances: Vertex plans to seek approval for its investigational medicine zimislecel for Type 1 diabetes in 2026 and release phase 3 study data for next-gen programs, further enhancing the diversity and competitiveness of its product lineup.
See More
Trump Administration Halts $259 Million Medicaid Funds to Minnesota
- Medicaid Funding Suspension: U.S. Vice President JD Vance announced the withholding of $259 million in Medicaid funds from Minnesota due to the state's failure to prevent the theft of federal funds, highlighting significant regulatory shortcomings in social welfare programs.
- State Government Pushback: Minnesota Governor Tim Walz retaliated on social media, accusing the Trump administration of attempting to punish states led by Democrats, illustrating the political tensions intertwined with healthcare policy.
- Audit Findings Impact: Medicaid program overseer Dr. Mehmet Oz stated that the payment halt follows audit findings, requiring Minnesota to propose a comprehensive corrective action plan within 60 days, emphasizing the stringent scrutiny of Medicaid fund usage.
- Nationwide Enrollment Pause: Additionally, a six-month nationwide pause on Medicaid enrollment for durable medical equipment suppliers was announced, aimed at addressing fraud risks among these providers, thereby intensifying oversight of the Medicaid system.
See More
Novo Nordisk Faces Market Pressures and Competition
- Market Share Decline: Despite being the first to launch a GLP-1 weight loss drug, Novo Nordisk's market share has fallen to about 40%, while rival Eli Lilly holds 60%, indicating a significant competitive disadvantage that could hinder future growth potential.
- Sales Forecast Downgrade: Novo Nordisk anticipates a 5% to 13% decline in sales and profits for 2026, marking the first annual sales drop since 2017, reflecting the company's vulnerability amid fierce competition and pricing pressures, which may further erode investor confidence.
- Drug Development Challenges: The disappointing trial results of Novo's next-generation weight loss drug CagriSema against Eli Lilly's Zepbound led to a more than 16% drop in stock price on the day of the announcement, significantly diminishing analysts' confidence in its commercial potential and possibly affecting future market performance.
- Increasing Pricing Pressure: The decline in GLP-1 drug prices in the U.S. is weighing on Novo Nordisk's revenue and profitability, especially since the U.S. market has accounted for over half of its total sales since 2023, making future pricing strategies critical for the company's ability to regain growth.
See More
Energy and Healthcare Stocks Underperform
- Energy Sector Decline: As of midday Tuesday, energy companies are down 0.4%, with ONEOK Inc (OKE) and EQT Corp (EQT) showing losses of 5.2% and 1.7%, respectively, indicating sector weakness that may impact investor confidence.
- ETF Performance Analysis: The Energy Select Sector SPDR ETF (XLE) is down 0.2% on the day but up 23.09% year-to-date, suggesting that despite short-term volatility, the long-term trend remains positive, potentially attracting more investor interest.
- Healthcare Sector Weakness: The healthcare sector is up 0.3% overall, yet Molina Healthcare Inc (MOH) and CVS Health Corporation (CVS) are down 4.2% and 3.7%, respectively, reflecting challenges faced by the sector that may influence future investment decisions.
- ETF Tracking Status: The Health Care Select Sector SPDR ETF (XLV) is down 0.3% on the day and up 2.09% year-to-date, showing some resilience despite short-term underperformance, which may provide investors with opportunities for risk diversification.
See More
